Vitamin market overview: Q2 trends and developments
The global vitamin market continues to navigate a mix of stability, price fluctuations, and supply chain adjustments. While some key vitamins show signs of declining prices, others remain stable due to factors such as import duties and currency fluctuations. BASF’s earlier-than-expected production resumption for vitamin E and vitamin A signals potential supply relief, but market sentiment remains cautious. Below is a detailed breakdown of the latest trends and updates for key vitamins (week 13).
In partnership with Feed Additive Prices
Vitamin E 50%
BASF has communicated that their vitamin E production will already be resumed in May instead of July. The force majeure will not be lifted straight away, first the supply chain will be replenished. The market is quiet currently and prices are stable to weak in all regions. Only in the USA the price is stable as any decline is offset by the imposed import duties. Q2 is mostly contracted.
Vitamin A 1000
The market has been weak recently and again last week the price came down in most regions. BASF has mentioned that they are on track to resume production in April 2025. Buyers are mostly on the sideline and buy hand-to-mouth. Q2 is largely contracted already.
Vitamin D3 500
Although stock levels are still low and overall availability is still tight, the market prices have shown some decline, although it is still at a high level. A good portion of Q2 is contracted by now, as buyers did not expect any significant nearby price relief.
Vitamin B2 80%
No changes are seen in the vitamin B2 market, compared to previous weeks. The market continues to display stability with consistent prices and a positive outlook on availability, bolstered by the recent approval of a new Chinese supplier for the EU market. Looking forward, notable fluctuations are not expected in the near term, with the majority of Q2 already fully contracted.
D-Calpan
No changes are seen in the vitamin B5 market. In most regions, the market remains stable. Only in Europe, the price has been a bit lower due to a more favorable EUR against the USD. In the USD the prices are slightly higher as additional import duties start to be seen. A good portion of Q2 has been contracted already.
Vitamin B3
Most of the weaker market sentiment of the past few weeks seems to be priced in by now. Although the overall sentiment remains weakish in general. In Europe the EUR-USD has been stronger, leading to lower prices as well. In the USA the market is stable as the price decline is offset by higher import duties. The recent incident at a vitamin B3 production facility did not influence the bearish trend. A decent portion of Q2 has been contracted but not all of it yet.
Biotin
The biotin market has shown stability over the past few months, consistently maintaining a historically low level. The current market remains balanced, with no significant fluctuations expected in the near term. Contracts for the second are mostly concluded.
Vitamin C 35% mono
Most vitamin C products have shown a declining trend lately in several regions. Although suppliers have a strong desire to increase prices or at least hold them steady, the current market conditions are allowing for some decline. The decline is least visible in the USA as import duties start to kick in, but in other regions like Europe the prices for vitamin C mono have been weaker lately. A decent portion of Q2 has been contracted already and there is a wait-and-see attitude for any further forward business.
